Rybelsus is a revolutionary new oral Type 2 diabetes medication containing the active ingredient semaglutide. This innovative product from Novo Nordisk was approved by Health Canada in 2019. Unlike injectable analogues, Rybelsus comes in tablet form and does not require daily injections. The convenience of pill administration promotes better patient adherence.

Our pages are protected with SSL to keep your personal and payment data safe.

256-bit encrypted connection

Reviewed by Olivia Irving, PhD, On February 19, 2024

T&Cs Apply

Rybelsus® tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels.